Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCLAT1 | Q6UWP7 | 1/20 | 0.39 |
| ▸ | POLQ | O75417 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.36 |
| ▸ | RELA | Q04206 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | KCNA3 | P22001 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3794393 | 0.85 | LMNA (0.46) | LCLAT1MEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL3832066 | 0.81 | PTPN1 (0.41) | LCLAT1POLB | |
| SCHEMBL3791164 | 0.79 | MAOB (0.44) | LCLAT1MEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL28191061 | 0.78 | PLK1 (0.54) | LCLAT1MEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL3247729 | 0.77 | NR4A1 (0.48) | LCLAT1ALDH1A1KMT2A | |
| SCHEMBL25403499 | 0.76 | HDAC8 (0.53) | LCLAT1MEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL3792765 | 0.75 | KDM4E (0.46) | LCLAT1ALDH1A1NPC1GAARAB9A | |
| SCHEMBL23175896 | 0.75 | LCLAT1 (0.40) | LCLAT1MEN1ALDH1A1KMT2ANPC1 | |
| SCHEMBL28059597 | 0.75 | LCLAT1 (0.40) | LCLAT1MEN1KMT2ANPC1RAB9A | |
| SCHEMBL16981794 | 0.75 | LCLAT1 (0.38) | LCLAT1MEN1ALDH1A1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8058425-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-11-15 | — | — | US | disclosed |
| US-8022065-B2 | Purine derivatives as kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-09-20 | — | — | US | disclosed |
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-08-25 | — | — | US | disclosed |
| US-7405305-B2 | Pyrrole-2, 5dione derivatives and their used as GSK-3 inhibitors | ELI LILLY AND COMPANY (US) | 2008-07-29 | — | — | US | disclosed |
| EP-1487822-B1 | PYRROLE-2,5-DIONE DERIVATIVES AND THEIR USE AS GSK-3 INHIBITORS | LILLY CO ELI (US) | 2007-08-01 | — | — | EP | disclosed |
| US-20050288321-A1 | Kinase inhibitors | ELI LILLY AND COMPANY | 2005-12-29 | — | — | US | disclosed |
| CN-1639152-A | Pyrrole-2, 5-dione derivatives and their use as GSK-3 inhibitors | LILLY CO ELI (US) | 2005-07-13 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207721-A1 | PURINE DERIVATIVES AS KINASE INHIBITORS | PNP, ADK, NME2 | LCLAT1 1948/4885POLQ 1388/4885MEN1 3239/4885 |
| US-20050288321-A1 | Kinase inhibitors | ABL1, MAP3K20, MAP3K19 | LCLAT1 1857/4885POLQ 1275/4885MEN1 1394/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.